Mr. Gaetan Angoh, Managing Director for Schering-Plough LTD (Singapore branch), said: "As a pioneer US pharma investor since 1995, Schering-Plough has leveraged on Singapore's solid infrastructure, skilled workforce and pro- business environment to expand to our current manufacturing campus. Today, we are one of the largest employers in Singapore's biomedical sciences industry with over 800 people."
In addition to chemical-based pharmaceuticals, Singapore has also built
up an impressive track record in biologics manufacturing. Within less than
two years, Genentech, GlaxoSmithKline, Lonza and Novartis announced their
decisions to site a total of five major biologics manufacturing facilities
amounting to US$1.5 billion in Singapore. The Singapore EDB, in partnership
with the industry, has put in place a comprehensive range of programs to
develop manpower and technological capabilities in support of biologics
Note 1: Abbott, Genentech, GSK, Lonza, MSD, SD, Novartis, Pfizer,
sanofi-aventis, Schering-Plough, Wyeth, Alcon
Reliable Skilled Manpower
Industry players in Singapore also work closely together to expand the talent pool to support the growth of the industry. In addition to joint campaigns to promote careers in the pharmaceutical and biotechnology industry, the companies lead industry-wide initiatives to upgrade the existing workforce and attract new entrants from other industries.
The Singapore Academy of GxP Excellence (SAGE) is one particularly
noteworthy initiative. Launched by the National University of Singapore
(NUS) in March 2008, the Academy works closely with industry
|SOURCE EDB Singapore and Agency for Science, Technology andResearch|
Copyright©2008 PR Newswire.
All rights reserved